-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A study published recently in Neurology, an authoritative journal in the field of neurology, aims to assess the relationship between circulating phenylalanine levels and brain function and neuropsychiasts in adult patients with phenylalania.
forward-looking cross-sectional study included early-stage phenyl ketoasteria patients over the age of 30, as well as age-matching controls.
subjects underwent extensive neurological assessments, neuropsytherapy and behavioral tests, sensory and motor induced power levels, and MRI tests.
, the concentration of neurodegenerative markers in CSF was assessed in a subgroup of 10 patients.
19 patients with phenylalanine urine (with a medium age of 41 years) with different phenylalanine levels (medium value 873μmol/L) were included in the study.
compared to the control group, they had higher rates of neurological symptoms, cognitive and behavioral abnormalities, autonomic neurological dysfunction, changes in neurophysiological indicators, and atrophy of the right pasal brain.
compared with the control group, patients with phenyl ketoarea had higher levels of A-beta 1-42 (p-0.003), T-Tau (p-lt;0.001) and P-Tau (p-0.032) in cerebrospinal fluid.
plasma phenylalanine levels were highly associated with the number of failed neuropsychological tests (r=0.64, p=0.003), neuropsychological symptoms (r=0.73, p=lt;001), the incubation period of the motor induced power potential (r=0.48, p=0.030) and the atrophy of the top leaf.
, it can be seen that the study provides strong evidence for the correlation between phenylalanine levels and clinical, neuropsychological, neurophysiological, biophysical and imaging changes in patients with phenylalanine urology.
.